People with chronic kidney disease (CKD) are at risk of severe outcomes, such as end-stage renal disease or cardiovascular disease, and CKD is a globally increasing health burden with a high personal and economic cost. Despite major progresses in prevention and therapeutics in last decades, research is still needed to reverse this epidemic trend. The regulation of water balance and the state of activation of the vasopressin system have emerged as factors tightly associated with kidney health, in the general population but also in specific conditions; among them, various stages of CKD, diabetes and autosomal dominant polycystic kidney disease (ADPKD). Basic science findings and also epidemiological evidence have justified important efforts towards interventional studies supporting causality, and opening therapeutic avenues. On the basis of recent clinical data, the blockade of V2 vasopressin receptors using tolvaptan in patients with rapidly progressing ADPKD has been granted in several countries, and a long-term randomized trial evaluating the effect of an increase in water intake in patients with CKD is on-going.
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Central experimental data
• Increased water intake alleviates kidney function decline and pathological damages in classical models of experimental nephropathy
• Lack of vasopressin and blockade of kidney vasopressin were associated with kidney protection in various kidney conditions
Introduction
Chronic kidney disease (CKD) is recognized as an increasingly important global public health issue because of the high absolute prevalence of the disease, expected to continuously increase. Moreover, CKD is a major risk factor for CVD and is responsible for important health expenses. Recently, a meeting hosted by the International Society of Nephrology stated that a global collaborative effort was 'required for a multifaceted action plan to combat the growing burden of CKD and its complications. More work is needed to understand the causes and pathophysiology of CKD at the individual patient level, and at the population level in regions where CKD is endemic' [1] . In that regard, the regulation of water balance and the state of activation of the vasopressin system have emerged as factors tightly associated with kidney health in various settings [2] [3] [4] . The evidence supporting these associations will be reviewed. A special focus will be given on interventional data supporting causality, and opening therapeutic avenues. Finally, the role of vasopressin in the progression of autosomal dominant polycystic kidney disease (ADPKD) will be described, as well as the efficacy of vasopressin antagonists in the disease.
Epidemiological evidence of the beneficial effect of hydration on kidney health in the general population Observational studies in man provide additional clues, especially when comparing large populations controlled for baseline variables. An initial retrospective analysis by Hebert et al. of 591 patients from the Modification of Diet in Renal Disease study (with a high percentage of patients with autosomal dominant polycystic kidney disease and, so, natural loss of concentrating ability due to cystic kidneys) reported a faster eGFR (estimated Glomerular Filtration Rate) decline was associated with a greater urine volume [5] . However, when this study was adjusted for diuretics, angiotensin-converting enzyme inhibitors, beta blockers and calcium channel antagonists, the association was lost, emphasizing the need for observational studies to control for baseline variables if looking for potential causal explanations. Since that report, there have been six observational studies in man [6] [7] [8] [9] [10] [11] . Strippoli et al. reported a protective effect of higher self-reported fluid intake on kidney function in two Australian communitybased cross-sectional studies [11] . CKD was defined as an eGFR < 60 mL min À1 per 1.73 m 2 . Fluid intake above the third quintile (>2.5 L day À1 ) or above the fifth quintile (>3.2 L day À1 ) was associated with a 30% or 50% reduction in CKD prevalence, respectively, as compared to the lower quintile (<1.8 L day
À1
). In another communitybased cross-sectional study based on the 2005-2006 US National Health and Nutrition Examination Survey, Sontrop et al. showed consistently a lower prevalence of CKD (eGFR < 60 mL min À1 per 1.73 m 2 ) in the participants reporting a higher water intake [10] . Interestingly, the association was observed only for the intake of plain water, but not when considering other beverages such as energy drinks, sugarsweetened or artificially sweetened drinks, tea, coffee, alcoholic beverages, fruit and vegetable juice, and milk or other dairy drinks. Strippoli's group in a second study reported no significant correlation between total fluid intake and longitudinal loss of kidney function [8] . A possible explanation for this seeming difference may be the power between the initial observations, which were fivefold greater than the following longitudinal study [8, 11] . A 7-year prospective longitudinal cohort study of over 2000 subjects controlled for 10 baseline variables showed higher urine volumes significantly predicted slower renal decline [6] . A recent chronic kidney disease cohort study of 273 patients reported an association between dialysis initiation and urine osmolality with higher osmolality predicting the onset of end-stage renal replacement therapy [9] . Also, a large cohort of 12 000 subjects followed for 5 years showed that chronic kidney disease correlated with baseline serum osmolality and implied that a decreased water intake with associated increase in osmolality correlated with the future onset of chronic kidney disease [7] .
Plasma copeptin as a biomarker of CKD risk in cohorts from the general population
Copeptin is co-secreted with vasopressin (it is the COOH-terminal portion of the pro-hormone). Copeptin is stable and, as such, is an easily measurable surrogate marker of vasopressin secretion. Copeptin and vasopressin plasma concentrations correlate strongly in a series of clinical conditions [12] [13] [14] . Plasma copeptin levels in the general population are higher in men than women, and are positively associated with body mass index, smoking, diabetes, or use of diuretic, and negatively associated with GFR, kidney size, the number of renal cysts, or self-reported water intake [13, 15] .
Plasma copeptin and microalbuminuria were positively associated in the Dutch population-based PREVEND study [16] . In this large cross-sectional study involving 7593 participants, microalbuminuria (urinary albumin excretion ≥30 mg per 24 h) was observed two times more frequently in the upper versus lower quintile of copeptin distribution. The association remained significant after adjustment on sex, age, blood pressure and eGFR, measured at baseline. In the Swedish prospective population-based Malmo Diet and Cancer StudyCardiovascular Cohort, associations were reported between plasma copeptin concentrations at baseline and new-onset microalbuminuria, in 2064 participants with a 16-year follow-up [17] . Of note, the association between copeptin and microalbuminuria persisted after adjustment on conditions such as diabetes and hypertension occurring during the follow-up. In a subset of the SKIPOGH (Swiss Kidney Project on Genes in Hypertension) study, plasma copeptin concentrations were inversely associated with eGFR and kidney length and positively associated with 24-h urinary albumin excretion, urine osmolality and with the presence of renal cysts [15] .
In the prospective DESIR (Donn ees Epid emiologiques sur le Syndrome d'Insulino-R esistance) study conducted in the French general population, with a 9-year follow-up, baseline plasma copeptin was associated with the risk of new-onset CKD, defined either as eGFR declining below 60 mL min À1 per 1.73 m 2 at least in one of the follow-up visits, or with the use of the criterion 'a Certain Drop in eGFR' proposed by the Kidney Disease Improving Global Outcomes (KDIGO) consensus group [18, 19] . The association was independent of other classical risk factors for CKD (age, sex, blood pressure and baseline renal function).
Plasma copeptin and diabetes-associated kidney disease
Plasma vasopressin is increased in patients with diabetes, either of type 1 or type 2, and in various rodent models of diabetes [20] . Loss of glucose in the urine and the osmotic diuresis may explain this observation in uncontrolled diabetes, but other causes are likely. It could result also from a relative contraction of extracellular volume induced by a diabetes-associated change in sensitivity of hypothalamic osmoreceptors [21] . From an adaptive perspective, high levels of vasopressin may be beneficial in the short term by limiting the water loss in urine induced by glycosuria [20] . In the long term, persistent stimulation of the vasopressin receptors might however induce kidney damages [22] . In the Dutch ZODIAC prospective study, which included 1328 patients with recent onset type 2 diabetes, Boertien et al. reported the association of baseline plasma copeptin with a faster decline in eGFR during a follow-up of 6.5 years [23] . In Sweden, in the Skaraborg Diabetes Register, plasma copeptin was again positively associated with eGFR decline at re-examination after 12 years of follow-up in people with newly diagnosed type 2 diabetes [24] . In the DIABHYCAR cohort (Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events and Ramipril), 3101 French participants were selected on the basis of type 2 diabetes and persistent increased urinary albumin excretion without renal failure at baseline [25] . The median duration of follow-up was 5 years and the main clinical outcome was a renal event, defined as the occurrence of the first event among the doubling of the serum creatinine level, or the requirement of haemodialysis or renal transplantation. Again, higher plasma copeptin at baseline was associated with a faster decline in eGFR (Fig. 1 ). These associations remained significant after adjustment on age, duration of diabetes, blood pressure, and levels of HbA1c, urinary albumin excretion and eGFR measured at recruitment. In further discrimination analysis using ROC curves, plasma copeptin and urinary albumin excretion at baseline performed similarly regarding the prediction of renal events (area under the ROC 0.73 and 0.77, respectively). When the markers were combined, the area under the ROC improved by 4% to 0.82.
Actually, the independent prognostic value of plasma copeptin is also relevant in type 1 diabetes. Recently, we measured plasma copeptin in two prospective cohorts of people with long-standing type 1 diabetes [26] . The clinical outcomes were ESRD, myocardial infarction or coronary revascularization, and mortality. At baseline, copeptin was associated with the prevalence of established and advanced diabetic nephropathy. During follow-up, copeptin was associated with the risk of ESRD, ischemic heart disease and all-cause mortality. Regarding ESRD, the predictive value of baseline copeptin was independent from classical risk factors (age, duration of diabetes, blood pressure, HbA1c, eGFR and urinary albumin excretion, measured at baseline).
Therapeutic use of water in chronic kidney disease
Shizhen Li, the author of Compendium of Materia Medica in 1578, wrote 'water is the best medicine'. The therapeutic use of water in chronic kidney disease is based on the biological rationale that water intake can suppress the pathophysiological effects of antidiuretic hormone (ADH, or vasopressin) [27, 28] . Vasopressin infusion increases proteinuria, renal plasma flow and hyperfiltration, whereas administration of antagonists reduces proteinuria and lower blood pressure and prevents renal injury [27, [29] [30] [31] [32] . The recent renaissance in interest in water and its relationship with vasopressin in patients with chronic kidney disease is largely due to two relatively recent discoveries, (i) of an antagonist for antidiuretic hormone action, which is well tolerated and (ii) a stable assay of a surrogate for vasopressin, copeptin, which makes it much easier to assess its action in experiments in animals and man [33, 34] . This section focuses on the role of water in preventing chronic kidney disease progression although there is strong evidence for a role in autosomal dominant polycystic kidney disease, reviewed in the next section, renal calculi and heat stress nephropathy, among other renal conditions [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] .
Bouby and Bankir reported in 1990 that a threefold increase in water intake ameliorates proteinuria, blood pressure rise and glomerulosclerosis in rats with 5/6 nephrectomy (the classic model of progressive renal injury in CKD) which was confirmed by Sugiura et al. in 1999 [27, 47] . Indirect evidence using the diabetes insipidus Brattleboro rat in the 5/6 nephrectomy model reveals protection from the classic hyperfiltration injury of CKD and the pathology can be restored by replacing the genetically absent vasopressin with a vasopressin analogue [48, 49] . Vasopressin antagonists prevent the pathological changes of CKD in the adriamycin nephropathy Wistar model [50] . Also in the 5/6 nephrectomy model treated with renin-angiotensin blockade, vasopressin antagonism has been shown to further reduce blood pressure, proteinuria and glomerulosclerosis [51] .
In 2015, results from a pilot randomized-controlled trial of Water Intake in chronic kidney disease Trial (WIT, NCT01753466) were reported [52] . This study showed that one could achieve an increase in hydration between groups (efficacy) with the hydration group increasing their urine volume by 0.7 L day À1 and the control group decreasing by 0.3 L day À1 with a difference of 0.9 L day
À1
. It also demonstrated that a modest increase in hydration was not associated with any significant toxicity, a change in serum osmolality or sodium concentration and did not change the quality of life of the subjects. The modest increase in water intake was associated with a significant reduction in plasma copeptin, a marker of vasopressin secretion [53] . Following the successful pilot, a large randomized control trial of water intake (WIT, NCT01766687) was registered and initiated with an update in June 2015 with Clinical Trials.gov. This is a parallel group randomized control trial of increased water intake with a 1-year follow-up with active coaching for 1 year followed by 1 year without active coaching and with patients being randomized to increased hydration or control after completing a short survey and undergoing a physical examination. They were tested at baseline, 3 weeks after randomization at 3-month intervals and a 24-h urine collection was performed at baseline, 6, 12 and 24 months after randomization. Eligibility criteria were stage 3 chronic kidney disease (eGFR between 30 and 60) and albumin:creatinine ratio of >2.8 in females or >2.0 mg mmol À1 in males, or a trace of protein or greater from a spot urine sample (ALBUSTIX â ). The target enrolment was 700 patients consented. Primary outcome measures were renal decline, assessed by change in eGFR and measured creatinine clearance between baseline and 12 months. The secondary outcome measures were albumin:creatinine ratio, baseline at 12 months and change in albumin:creatinine ratio between baseline and 12 months, rapid decline in renal function (eGFR declining >5% between baseline and 12 months) and there were pre-specified outcome measures including change in body mass index, blood pressure, copeptin at baseline and 12 months, HbA1c, long-term renal decline, effective fluid coaching on adherence and change in urine volume between 12-and 24-month followup. To encourage retention and adherence, monthly contact occurs with the coaching team that focused on participants'm24-h urine osmolality and volume verified by their urine colour chart. Baseline variables were balanced between the groups and as of the current date we have approached over 2300 subjects and excluded 1569 due to either ineligibility or refusal. We obtained consent of 822 patients and in the 2-week pre-work-up including their 24-h urine collection 91 withdrew from the study, 81 were shown to be ineligible and 629 were randomized. At the present date, we have 273 subjects in the hydration group and 285 in the control group. (Fig. 2) There have been 71 withdrawals and the preliminary assessment in the WIT Study in CKD indicates good separation between groups in terms of urine volume (Fig. 3) . On the basis of power analysis using these preliminary data, there will likely be scientifically reliable data testing a causal association between fluid intake and kidney function in human CKD. This randomized control trial will be concluded in April 2017.
Autosomal dominant polycystic kidney disease: a target for V2 receptor blockade
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited nephropathy, with an estimated prevalence ranging from 1 : 500 to 1 : 4000 in various populations, characterized by the development of multiple cysts in the kidneys [54] . The disease progresses slowly, with an ineluctable increase in total kidney volume (TKV) preceding the onset of renal failure usually in the 4th-6th decades of life. More than 70% of patients reach end-stage renal disease, with TKV and renal cyst growth being the strongest predictors of renal function decline. ADPKD is responsible for 7-10% of the patients requiring a renal replacement therapy [55] . Mutations in two genes, PKD1 and PKD2, account for 85% and 15% of the affected families, respectively. The PKD1 and PKD2 genes encode integral membrane proteins, polycystin-1 and polycystin-2, which form a complex localized in various cellular domains. The latter include the primary cilium of renal tubular epithelial cells where the polycystins mediate calcium fluxes in response to mechanical or chemical stimuli. Mutations in PKD1/PKD2 alter intracellular calcium homeostasis and lead to cystogenesis by a combination of increased cellular proliferation, abnormal fluid secretion and dedifferenciation of tubular cells [54] [55] [56] . Since the cysts are anatomically separated from the tubule from which they derive, the intracystic fluid does not originate from the glomerular filtrate but rather from a transepithelial fluid secretion [57] .
The ADPKD cysts derive from 1% to 3% of the nephrons. They potentially involve all nephron segments although an important fraction of the cysts derives from the collecting ducts [58, 59] . The kidney cysts already exist in utero but usually become clinically detectable in young adulthood. The follow-up of ADPKD patients with magnetic resonance imaging (MRI) has established that cysts increase at a stable rate of~5% per year [60] . Despite the exponential growth of kidney cysts, compensatory hyperfiltration in non-cystic nephrons maintains the glomerular filtration rate (GFR) stable -usually until the age of 30-40 years [54] .
Defective urinary concentration mechanisms in ADPKD
Defective urinary concentration is frequently observed in patients with ADPKD and is more severe in those harbouring large kidneys on ultrasound analysis [61] . A peripheral resistance to the antidiuretic hormone vasopressin (or AVP) has been suggested, in view of higher vasopressin levels observed in ADPKD patients at baseline and after hypertonic saline infusion [62] . An explanation for such peripheral resistance to vasopressin is the existence of cystic lesions impairing the establishment of the interstitial osmotic gradient driving water reabsorption in the distal nephron [63] . In fact, Ho et al. showed defects both in the release of vasopressin in response to plasma osmolality (central component) and in the V2 receptor (V2R)-mediated response (nephrogenic component) in adult and paediatric ADPKD patients with intact GFR, compared to non-affected controls [64] . The peripheral resistance to vasopressin is correlated with TKV in adults, whereas the presence of cysts or their number is not a prerequisite for the defective osmoregulation in ADPKD children. Furthermore, the relationship between plasma osmolality and vasopressin levels, obtained after water deprivation, was severely blunted in ADPKD patients, suggesting a central defect altering the release of vasopressin in response to increased osmolality [64] . The fact that both Pkd1/Pkd2 (mouse) and PKD1/PKD2 (human) genes are expressed in the supraoptic, suprachiasmatic and paraventricular nuclei that synthesize and release vasopressin could provide a basis for a central osmoregulation defect in ADPKD [64] .
Role of cAMP and vasopressin in ADPKD
Increased concentrations of 3 0 -5 0 -cyclic adenosine monophosphate (cAMP) play a major role in the progression of renal cystic disease in ADPKD [65, 66] (Fig. 4) . Stimulation of the V2R by vasopressin is the major source of cAMP production in the distal nephron [67] . Haploinsufficiency in polycystin-1 in Pkd1 +/À mice is associated with excessive vasopressin signalling, causing increased phosphorylation and recruitment of aquaporin-2 water channels and inappropriate antidiuresis [68] . The increased cAMP levels may arise from decreased intracellular Ca 2+ concentration caused by mutations in polycystins, via the downregulation of Ca 2+ -dependent phosphodiesterase PDE1 and stimulation of the Ca 2+ inhibitable adenylyl cyclase 6 (AC6) [69, 70] . The upregulation of cAMP stimulates proliferation and growth of ADPKD cells and drives transepithelial chloride and fluid secretion, through activation of protein kinase A (PKA) and pathways including the mitogen-activated protein kinase (MAPK) kinase MEK and the extracellular signal-regulated kinase ERK, mTOR and Wnt-b-catenin, STAT3 and possibly PAX2 signalling [69] .
The involvement of the V2R pathway in ADPKD was demonstrated by inhibiting renal cyst development in various rodent models treated with V2R antagonists mozavaptan and/or tolvaptan) [54, 55] . Suppression of endogenous vasopressin by high water intake attenuates the progression of PKD in the PCK rat [71] . Likewise, cyst development is markedly inhibited in PCK rats crossed to Brattleboro rats, whereas administration of the V2R agonist 1-deamino-8-d-arginine vasopressin fully rescues the cystic phenotype [72] . The results motivated the initiation of clinical trials testing whether the use of V2R antagonists effectively inhibits cystogenesis in ADPKD patients.
Clinical trials of V2R antagonists in ADPKD
Until recently, treatment of ADPKD was symptomatic, focusing on the complications (e.g. hypertension, kidney pain, infections, intracranial aneurysm) associated with the disease [73] . Based on the efficacy of V2R blockade in animal models, small clinical trials first assessed the safety and pharmacokinetics of the selective V2R inhibitor tolvaptan in adult patients with ADPKD. Twice daily administration is necessary to block V2R activation throughout a 24-h period as reflected by urine hypotonicity. A phase 2, open-label, 3-year trial showed beneficial changes in TKV and eGFR in 63 patients compared to historical controls [74] . All patients experienced adverse events, mainly related to aquaresis. A subsequent study showed that short-term (1 week) treatment with tolvaptan was associated with an aquaresis and a reduction of GFR, a reduced clearance in uric acid and a 3.1% reduction in kidney volume as assessed by MRI [75] .
A phase 3, multicentre, randomized, double-blind, placebo-controlled trial tested the efficacy of tolvaptan in ADPKD (TEMPO, Tolvaptan Efficacy and Safety in Management of ADPKD and its Outcomes, 3 : 4), conducted at 129 sites in 15 countries [76] . In this trial, 1445 patients with ADPKD and rapid disease progression (TKV of at least 750 mL, age 18-50 years) but preserved renal function (eCrCl > 60 mL min
À1
, Cockroft-Gault) were randomized to receive either placebo or tolvaptan. Split doses of 45/15 mg were titrated at weekly intervals to 60/30 and 90/30 mg, if tolerated, and maintained for 36 months. All subjects were encouraged to drink water in advance of thirst. Biological parameters were measured every 4 months and renal MRIs every year. In this study, tolvaptan was shown to slow the rate of TKV growth (primary endpoint) by 49%. The treatment effect of tolvaptan on TKV was greatest from baseline to year 1 and remained significant for the two subsequent years. The administration of tolvaptan was also reflected by a slower decline of renal function (reciprocal serum creatinine) and a 36% lower risk of kidney pain. Subjects taking tolvaptan are presented with more frequent adverse events related to aquaresis (polyuria, thirst, nocturia), and fewer adverse events related to ADPKD (pain, haematuria, UTI). They also showed a higher frequency of discontinuation of the study drug, mostly related to aquaretic adverse events and elevation of aminotransferases in plasma. Patients treated with tolvaptan also showed an increase in serum sodium and uric acid levels, and in the frequency of gout [76] . Based on the results of the TEMPO 3 : 4 trial, the regulatory authorities in Japan, Canada, United Kingdom, Europe (EMA) and Switzerland recently granted marketing authorization for the use of tolvaptan (JINARC â ) for ADPKD, in patients characterized by rapid disease progression [77] .
Post hoc analyses of the TEMPO 3 : 4 trial
A subsequent analysis of the TEMPO 3 : 4 trial showed that tolvaptan was similarly effective in reducing the rate of increase in TKV in patients with ADPKD who had CKD1-CKD3 at baseline. The reduction in the rate of kidney growth was accompanied by a slower rate in the decline of eGFR, reflected by lower on-treatment eGFR slopes in patients with CKD2 and CKD3 [78] . A further post hoc study revealed that tolvaptan decreased albuminuria compared with placebo, independent of blood pressure. Treatment efficacy of tolvaptan on changes in TKV and eGFR was more readily detected in patients with higher albuminuria [77] .
A recent study investigated the determinants of baseline urine osmolality (Uosm) and its value as a severity marker of ADPKD; the factors influencing the response to tolvaptan; and whether change in Uosm associated with key end points of the TEMPO 3 : 4 trial [79] . At baseline, lower Uosm independently associated with female sex, presence of hypertension, lower eGFR, higher total kidney volume (TKV) and higher age. Tolvaptan consistently reduced Uosm by 200-300 mOsm kg À1 over 36 months. The Uosm response to tolvaptan depended on baseline eGFR and Uosm. Subjects with greater change in Uosm experienced a significant reduction in clinical progression events. Among subjects receiving tolvaptan, those with a greater suppression of Uosm had slower renal function decline. Assessment at follow-up, off medication, revealed a significant decrease in Uosm in both placebo and treated groups. Tolvaptan significantly increased plasma osmolality, which returned to baseline at follow-up.
High water intake in ADPKD
A sustained, high water intake is considered of potential value in ADPKD patients, as it would suppress endogenous AVP, thus lower cAMP levels in cyst-lining cells [63] . The inhibition of endogenous vasopressin by high water intake would also reduce non-specific effects (V1a and V1b-mediated) caused by increased endogenous vasopressin associated with chronic use of selective V2R antagonists [80] . As a proof-of-principle, high water intake (10 weeks) in the PCK rat reduced AVP, V2R expression and cAMP-mediated pathways, reflected by a~30% decrease in kidney/body weight ratio and by improved renal function [71] . Patients with ADPKD show a normal capacity to dilute urine -and thus to inhibit AVP release -upon water loading [35, 44, 64] . Recommendations for intake of water in ADPKD based on preclinical studies have been proposed [63] . The water intake should aim to low urinary osmolality (<250 mOsm kg À1 H2O), in ADPKD patients with an eGFR > 30 mL min À1 per 1.73 m2. The water intake should be split over day time, with frequent voiding. Monitoring plasma sodium and urine osmolality should be advised. Compliance would be a challenge, since thirst is not driving the fluid intake like in diabetes insipidus or V2R inhibition [69] .
Conclusion
Epidemiological evidence is very strong to support an association between inappropriately low fluid intake, and more specifically water intake, and chronic kidney damages, in various conditions. Experimental data, most of them originating from Bankir's group in France for CKD or diabetic kidney disease, and clinical data, accumulating since the availability of the copeptin assay, strengthen the hypothesis according to which this association is causal, and mediated by the activation of the vasopressin system. In that regard, the role of vasopressin in ADPKD is particularly central. Not surprisingly, ADPKD is the most advanced disease for a therapeutic use of vasopressin system blockade with the results of the TEMPO 3 : 4 trial, but this concept is also currently explored in CKD of various causes through a lifestyle intervention targeting daily water intake (the Water Intake Trial in CKD, NCT01766687). This is a fascinating example of translational medicine, from very early experimental and clinical observations, to potential changes in clinical recommendations in very frequent diseases. However, further studies (some of them are on-going) are needed to state the relevance of the proposed lifestyle or pharmacological interventions.
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